Obagi / Nu-Derm Clear
HYDROQUINONE USP 4%
The first manufactured prescription drug in this register rather than a compounded blend, and it shows: hydroquinone USP 4% stated as 40 mg/g, a full inactive list, real contra-indications, and the best sunscreen sentence anyone here has written. Two things are in neither the page nor the label — ochronosis, and the fact that the FDA has not found this drug safe and effective.
Worth buying for a specific person with a specific problem. Read who.
ASSESSED ON 75% OF THE MODEL. 2 CRITERIA LEFT UNSCORED — SEE SCORING FOR WHY.
Agree a stop date with the prescriber before you start. The label tells you when to give up if it is not working; nothing tells you when to stop if it is.
The verdict
This is the first product in twenty-six reviews that is a manufactured drug rather than a compounded blend, and the difference is immediately visible. The active is stated as hydroquinone USP 4%, and then restated the way a label does it — 40 mg per gram. The full inactive list is printed. Contra-indications, warnings, precautions, pregnancy category, nursing mothers and paediatric use are all on the page, not behind a click. A complete Prescribing Information PDF is linked. After twenty-five products whose composition had to be inferred, negotiated or looked up elsewhere, reading this page is a different experience.
The formulation is the other pleasant surprise. Hydroquinone oxidises, and a hydroquinone product is only as good as the antioxidant system protecting it. This one runs ascorbic acid, sodium metabisulfite and BHT, and publishes all three where they can be checked. We credited a competitor for exactly this system when we had to infer it; here it is simply listed. The page also carries the single best sentence about sun protection in this register: 'Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure sustains melanocytic activity.' It gives the instruction and the mechanism in one line.
Two omissions sit against all of that, and they are specific to this drug. There is no mention of exogenous ochronosis — the paradoxical blue-black darkening that is hydroquinone's signature long-term risk — anywhere on the page or in the linked label. And there is no statement of the product's regulatory status. Obagi Nu-Derm Clear is not an FDA-approved drug; the FDA's own listing for it carries the disclaimer that it 'has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA'. The page says 'RX ONLY' and links a label, both of which imply the opposite.
The linked label is also sixteen years old. It is marked Rev. 07/10, and its ingredient list for this product does not match the ingredient list printed on the page above it. One of those two documents is out of date, and a buyer has no way to tell which.
- Hydroquinone USP 4%, stated on the page and restated as 40 mg per gram.
- A full inactive ingredient list printed on the product page.
- A published antioxidant system — ascorbic acid, sodium metabisulfite, BHT — appropriate to a hydroquinone preparation.
- Complete Important Safety Information on the page: contra-indications, warnings, precautions, pregnancy, nursing, paediatric.
- 'Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure sustains melanocytic activity' — instruction plus mechanism, in one sentence.
- An explicit sulfite warning covering anaphylactic and asthmatic reactions, which most brands would have omitted.
- Pregnancy Category C stated, with the honest admission that systemic absorption is not known.
- A complete Prescribing Information PDF linked from the page.
- The label instructs a 24-hour patch test before use — the only product here that does.
- Fill size and a stopping rule both exist in the linked label: 2 oz / 57 g, and discontinue if no improvement at 8–12 weeks.
- Genuine physician gating rather than a ten-minute online questionnaire.
- No mention of exogenous ochronosis on the page or anywhere in the linked label.
- No statement that the FDA has not found this drug safe and effective — which its own FDA listing says.
- No price published anywhere on the page.
- The linked Prescribing Information was last revised in July 2010.
- The page's inactive list does not match the label's list for the same product — it includes phenyl trimethicone and PPG-2 myristyl ether propionate, which the label assigns to a different product in the range.
- The fill size is in the label but not on the page.
- The label's only stopping rule is about futility — stop if it is not working — not about cumulative exposure if it is.
- Sodium lauryl sulfate and four parabens on skin that is being deliberately irritated.
- Monotherapy, when the best melasma evidence is for triple combination.
Every active, assessed
- Hydroquinone USP4% (40 mg/g)
Tyrosinase inhibitor — reversible depigmentation by inhibiting enzymatic oxidation of tyrosine to dopa
- BENCHMARK
- 4% is the conventional prescription strength
- ASSESSMENT
- The reference concentration of the reference drug, stated the way a pharmacopoeial label states it. This is what every compounded hyperpigmentation product in this register is imitating, and it is the first time we have been able to read the number, the units and the excipients together. The concerns are not about the dose. They are that nothing here tells you how long to stay on it, or what ochronosis is.
- Ascorbic acid, sodium metabisulfite, BHTNOT INDIVIDUALLY STATED
Antioxidant system — protects hydroquinone from oxidation in the container and on the skin
- BENCHMARK
- An appropriate system for a hydroquinone preparation
- ASSESSMENT
- Exactly the right supporting cast, published rather than inferred. Note the trade-off Obagi discloses honestly: sodium metabisulfite is a sulfite, and the page warns it may cause allergic-type reactions including anaphylactic symptoms and life-threatening asthmatic episodes in susceptible people, more frequently in asthmatics. That is a real warning about a real ingredient, and most brands would have left it out.
| ACTIVE | CONC. | BENCHMARK | ASSESSMENT |
|---|---|---|---|
| Hydroquinone USPTyrosinase inhibitor — reversible depigmentation by inhibiting enzymatic oxidation of tyrosine to dopa | 4% (40 mg/g) | 4% is the conventional prescription strength | The reference concentration of the reference drug, stated the way a pharmacopoeial label states it. This is what every compounded hyperpigmentation product in this register is imitating, and it is the first time we have been able to read the number, the units and the excipients together. The concerns are not about the dose. They are that nothing here tells you how long to stay on it, or what ochronosis is. |
| Ascorbic acid, sodium metabisulfite, BHTAntioxidant system — protects hydroquinone from oxidation in the container and on the skin | NOT INDIVIDUALLY STATED | An appropriate system for a hydroquinone preparation | Exactly the right supporting cast, published rather than inferred. Note the trade-off Obagi discloses honestly: sodium metabisulfite is a sulfite, and the page warns it may cause allergic-type reactions including anaphylactic symptoms and life-threatening asthmatic episodes in susceptible people, more frequently in asthmatics. That is a real warning about a real ingredient, and most brands would have left it out. |
Scoring
- EVIDENCE FOR THE ACTIVEWEIGHT 30%82/100
Hydroquinone 4% is the best-evidenced single agent for hyperpigmentation and this is the reference formulation of it, with the labelled indications matching the literature — melasma, chloasma, senile lentigines, freckles. Held back because it is monotherapy, and triple combination outperforms hydroquinone alone; because the product is FDA-unapproved and has therefore never been through an efficacy review; and because the supporting label material dates from 2010.
- FORMULATION INTEGRITYWEIGHT 20%80/100
The best-formulated hydroquinone product we have assessed. A single active at the correct strength, with a published antioxidant system — ascorbic acid, sodium metabisulfite, BHT — that is precisely what the molecule needs, plus lactic acid to hold the pH where hydroquinone is stable. Marked down because the page's ingredient list does not match the linked label's, and because sodium lauryl sulfate and four parabens are a dated excipient choice on skin already being irritated.
- DISCLOSUREWEIGHT 15%74/100
By some distance the most complete composition and safety disclosure of any prescription product here: concentration in percent and mg/g, full inactive list, contra-indications, warnings including the sulfite anaphylaxis risk, pregnancy category C, nursing and paediatric sections, and the sunscreen mechanism. Held back hard by three absences — no ochronosis anywhere, no statement that the FDA has not found this drug safe and effective, and no price at all — plus a fill size and a stopping rule that appear only in a sixteen-year-old linked label.
- TOLERANCE IN USEWEIGHT 15%NOT ASSESSED
Not assessed. The label's own account — transient reddening and mild burning, occasional contact dermatitis — is consistent with the literature, and the instruction to patch test for 24 hours before use is one no other brand here gives.
- TEXTURE & WEARWEIGHT 10%NOT ASSESSED
Not assessed. Requires the product in hand.
- COST PER APPLICATIONWEIGHT 10%40/100
The fill size is genuinely published — 2 oz, 57 g — which almost nothing else in this register manages, and twice-daily dosing is stated, so cost per application would be computable if a price existed. None does. Obagi publishes no price on this page and sells nothing from it, directing buyers to a physician instead. A reader can work out everything about this product except what it will cost them.
What it is
A manufactured prescription cream containing hydroquinone USP 4%, indicated for the gradual bleaching of hyperpigmented skin — melasma, chloasma, senile lentigines, freckles. It is dispensed through a physician rather than sold online, and it is part of the Nu-Derm system alongside Blender and Sunfader, which contain the same 4% hydroquinone.
This is what a drug page looks like
Twenty-five reviews of compounded telehealth products have accustomed us to arguing about whether a concentration exists. Here is the relevant passage from this page, quoted whole:
ACTIVE INGREDIENT: hydroquinone, USP 4% (40 mg/g). INACTIVE INGREDIENTS: ascorbic acid, BHT, butylparaben, cetyl alcohol, disodium EDTA, glycerin, lactic acid, methylparaben, phenyl trimethicone, PPG-2 myristyl ether propionate, propylparaben, saponins, sodium lauryl sulfate, sodium metabisulfite, TEA-stearyl alcohol, tocopheryl acetate, water (aqua)
Obagi Nu-Derm Clear product page
That is a pharmacopoeial active with its unit strength, followed by every excipient. Beneath it the page prints contra-indications, warnings, precautions, a pregnancy category, a nursing mothers section and a paediatric section — the structure of a package insert, on the page you read before buying. Nothing else in this register is presented this way, because nothing else in this register is a manufactured drug.
Hydroquinone oxidises readily; a hydroquinone cream that has gone brown is a cream that has stopped working. This one carries ascorbic acid, sodium metabisulfite and BHT — a three-part antioxidant system — plus lactic acid holding the pH where hydroquinone is stable. We previously credited Musely for the same system, which we had to infer from a third-party listing. Here it is printed. This is the best-formulated hydroquinone product we have looked at.
The sun protection line deserves its own mention because it is the best-written sentence about sunscreen in the register: 'Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure sustains melanocytic activity.' It is not an afterthought in an FAQ. It explains why, in one clause, and the why is what makes people comply.
The metabisulfite warning is the same story. Obagi could have listed the ingredient and moved on. Instead the page states that it is a sulfite which may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes, and that sensitivity is more common in asthmatics. That is a company disclosing a genuine hazard in its own product.
The word that is not here
Exogenous ochronosis is the paradoxical outcome of prolonged hydroquinone use: a blue-black darkening of the treated skin, difficult to treat and sometimes permanent, and the specific reason every clinical source treats hydroquinone as a course rather than a maintenance product. It is the whole basis on which this register criticised a competitor for selling 12% hydroquinone on an open-ended subscription.
We searched the product page and the full linked Prescribing Information. The word ochronosis appears in neither.
The label does contain a stopping rule, and it is worth being precise about what it says: 'If no improvement is seen after 8-12 weeks of treatment, use of this product should be discontinued.' That is a futility rule. It tells you when to give up if the drug is not working. It says nothing at all about when to stop if it is working, which is the question ochronosis actually poses.
The linked Prescribing Information is marked Rev. 07/10. The systematic review literature this register cites on hydroquinone-associated ochronosis was published in 2022. A label revised in July 2010 cannot be expected to reflect it — but a product page published in 2026 and linking that label could, and does not.
A third answer to the same question
Three consecutive reviews have now turned on one question: does the page tell you what the product legally is?
Dermatica answers it wrongly, running an 'FDA REGULATED' badge across pages selling compounded formulas that are not FDA-approved. Ro answers it correctly and prominently, printing 'Compounded medication. Not FDA-approved.' directly beneath its price. Obagi does not answer it at all.
Obagi Nu-Derm Clear is not an FDA-approved drug. It is a marketed unapproved drug — legal to sell, prescribed for decades, with a National Drug Code and a proper label, and never taken through a New Drug Application. The FDA's own listing of this product carries the standard disclaimer: the drug 'has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA'.
None of that appears on Obagi's page. What appears instead is 'RX ONLY', a link marked Read Safety Information, and a full Prescribing Information PDF — three signals that, taken together, read as a fully approved medicine to anyone who has not spent an afternoon in the FDA's databases. We are not suggesting deception; this is the industry norm for a category of drug that predates modern approval pathways. But Ro proved a fortnight's worth of reviews ago that the sentence can simply be written, and it costs one line.
Nine facts a buyer of a 4% hydroquinone product needs: concentration, full inactive list, contra-indications, pregnancy status, sunscreen instruction, fill size, a treatment duration rule, the ochronosis risk, and the product's FDA approval status. Five are on the page — more than any other product in this register manages. Two more are in the linked 2010 label. Two are in neither document.
Two documents, one product, different ingredients
The page and the label it links disagree about what is in the bottle.
The page's inactive list for Clear includes phenyl trimethicone, PPG-2 myristyl ether propionate and TEA-stearyl alcohol. The label's list for Clear includes none of those; it has stearyl alcohol instead. Two of the three — phenyl trimethicone and PPG-2 myristyl ether propionate — appear in the label under Blender, a different product in the same range.
The innocent explanation is the likely one: the product was reformulated at some point in the last sixteen years and the 2010 insert has not caught up. That is entirely plausible and it is still a problem, because both documents are published side by side by the same company, describing the same product, in 2026. Someone with a paraben question or a silicone sensitivity cannot resolve it from Obagi's own materials.
You cannot find out what it costs
There is no price on this page. There is no add-to-bag. There is a Find a Physician button and a line explaining that a prescription is required and that you should contact your healthcare provider to purchase.
This is the traditional physician-dispensed model and there are respectable arguments for it — a prescriber assesses you, supervises the course and decides when it ends, which is exactly the oversight we have spent twenty-five reviews saying hydroquinone needs. Obagi's version of the prescription gate is the most real one in this register.
It does mean the value criterion cannot be met. The fill size is published, in the label: 2 oz, 57 g. The dosing is published: a thin application twice daily. Everything needed to compute cost per application exists except the cost, and a reader has to commit to an appointment before they can learn it.
If you are considering it
- Agree a stop date with the prescriber before you start, not after. The label's 8–12 week rule is about giving up, not about stopping when it works.
- Ask specifically about ochronosis and about cycling off. Neither document raises it and the prescriber should.
- Read the linked Prescribing Information — it is short, it is a real label, and it tells you things the page does not.
- Do the 24-hour patch test the label asks for. Nobody else in this register asks and it takes a day.
- If you are asthmatic or sulfite-sensitive, take the metabisulfite warning seriously and raise it before you fill the prescription.
- Wear sunscreen daily and understand why: without it, minimal light exposure keeps the melanocytes producing and the drug is working against you.
- Treat small areas at a time, as the label instructs, rather than the whole face at once.
- Ask the price before the appointment if you can, because the page will not tell you.
Where we stand
At 74 this is the highest-scoring hyperpigmentation product in the register and the highest-scoring product outside CoreAge Rx and Honeydew, and it earns that mostly by being what the others are imitating. A manufactured drug, at a pharmacopoeial concentration, with a published excipient list, a real label, an antioxidant system that suits the molecule, and a physician between the patient and the bottle. Everything the compounded telehealth products approximate, this does properly.
What keeps it from higher is not formulation, it is candour about two specific things. A drug whose defining long-term risk is ochronosis should say the word somewhere. And a drug the FDA has not found safe and effective should say that too — particularly on a page that otherwise reads exactly like an approved medicine's.
Add a line about ochronosis and cycling. Add the sentence Ro already writes about approval status. Refresh a sixteen-year-old insert so it agrees with the ingredient list above it, and put the fill size and a price on the page. That is a morning's work on a genuinely good product, and it would make this the first prescription hyperpigmentation treatment we recommend without conditions.
Who this is for
- Someone with melasma or lentigines who wants the reference hydroquinone product and a physician actually involved in dispensing it.
- Someone who wants to read the full composition and the full label before starting — this is the only page here that lets them.
- Someone who will agree a review date and a stop date with the prescriber at the outset, since the label will not supply one.
- Someone who will wear sunscreen daily, which this page explains better than any other.
- Someone with no history of sulfite sensitivity or asthma, given the metabisulfite warning.
- You are pregnant or breastfeeding. Safety has not been established and the label says so.
- You are sulfite-sensitive or asthmatic — the metabisulfite warning is specific and serious.
- You want to use it indefinitely. Nothing here sets a cumulative limit, and ochronosis is the reason one is needed.
- You need to know the price before committing to a physician visit.
- You have extensive areas to treat. The label says treatment should be limited to relatively small areas at one time.
Agree a stop date with the prescriber before you start. The label tells you when to give up if it is not working; nothing tells you when to stop if it is.
This is an editorial assessment of published information about a prescription product. It is not a diagnosis, not a prescription and not a substitute for your own prescriber. Hydroquinone and tretinoin are drugs. Decisions about them belong with a clinician who has seen your skin.
Sources
- S-01Obagi — Nu-Derm Clear product page The 4% and 40 mg/g statements, the full inactive ingredient list, the on-page Important Safety Information including the sulfite and sunscreen warnings, Pregnancy Category C, the RX ONLY marking, and the absence of price, fill size, ochronosis and FDA approval status. Read 27 July 2026.
- S-02Obagi — Nu-Derm Clear, Blender and Sunfader full Prescribing Information (Rev. 07/10) The label linked from the product page. Source of the 8–12 week futility rule, the 2 oz / 57 g fill size, NDC 62032-101-36, the twice-daily dosing, the 24-hour patch test instruction, and the Clear ingredient list that differs from the one printed on the page.
- S-03DailyMed — Obagi Nu-Derm Clear, Blender and Sunfader (hydroquinone USP 4%) The FDA listing carrying the unapproved-drug disclaimer: this drug 'has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA'.
- S-04Ishack et al. — Exogenous ochronosis associated with hydroquinone: a systematic review (Int J Dermatol, 2022) The ochronosis literature that neither the product page nor the 2010 label mentions.
- S-05FDA — protecting consumers from potentially harmful OTC skin lightening products The regulatory position on hydroquinone in the United States, and the reason a prescription gate on a 4% product is the correct side of the line.
- S-06Ro — Custom Rx Treatment product page The comparison used on regulatory candour: 'Compounded medication. Not FDA-approved.' printed beneath the price.